Straits Times Index
3,144.76 -38.85 (-1.22%) S&P 500
5,064.90 +3.08 (+0.06%) Dow
37,867.61 +132.50 (+0.35%) Nasdaq
15,903.44 +18.42 (+0.12%) Bitcoin USD
62,894.52 -113.96 (-0.18%) CMC Crypto 200
885.54 0.00 (0.00%)
RedHill Biopharma Ltd. (RDHL)
| Previous close | 0.4041 |
| Open | 0.3800 |
| Bid | 0.2800 x 200 |
| Ask | 0.4690 x 200 |
| Day's range | 0.3000 - 0.3910 |
| 52-week range | 0.2570 - 3.2800 |
| Volume | |
| Avg. volume | 1,225,012 |
| Market cap | 12.24M |
| Beta (5Y monthly) | 3.46 |
| PE ratio (TTM) | 0.10 |
| EPS (TTM) | 4.0000 |
| Earnings date | 10 Jun 2024 - 14 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 760.00 |
Simply Wall St.RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)
RedHill Biopharma ( NASDAQ:RDHL ) Full Year 2023 Results Key Financial Results Net income: US$23.9m (up from US$71.7m...
PR NewswireRedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its full year 2023 financial results and operational highlights and associated filing of its annual report on Form 20-F for the year ended December 31, 2023.
- PR Newswire
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into definitive agreements with private investors for the purchase and sale, at a premium, of 2,144,487 of the Company's American Depositary Shares ("ADSs"), each ADS representing four hundred (400) ordinary shares, par value NIS 0.01 per share, of the Company, and warrants to purchase up to an aggregate of 2,144,487ADSs, at a purchase price of $0.58289 p
